ProQR(US:PRQR)2026-03-12 11:22Financial Performance - The company reported net losses of €42,184,000, €27,763,000, and €27,735,000 for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of €467,506,000 as of December 31, 2025[40]. - The company has not generated, and does not expect to generate, any product revenue for the foreseeable future, relying on government research grants and collaboration agreements for income[42]. - The company anticipates continuing to incur significant operating losses due to research and development costs associated with its RNA editing platform and product candidates[43]. - The company may face substantial liabilities from product liability claims, which could adversely affect its financial condition and share price[197]. - The company has a risk of losing a material portion of its net operating losses due to regulatory changes, even if it attains profitability[199]. - The trading price of the company's ordinary shares reached a high of $24.99 per share on March 10, 2015, but decreased to as low as $0.56 per share on May 11, 2022[204]. - The company may face potential volatility in its share price due to various factors, including clinical trial results and regulatory actions[204]. - The company has never declared or paid cash dividends on its ordinary shares, and capital appreciation will be the sole source of potential gain for shareholders in the foreseeable future[219]. Research and Development - The company has focused its resources exclusively on the development of its RNA editing platform since August 2022, ceasing clinical development of sepofarsen and ultevursen, which were sold to Laboratoires Théa S.A.S. in December 2023[40]. - The company has allocated significant resources to the phase 1 clinical development of its lead product candidate AX-0810, targeting na-taurocholate cotransporting polypeptide (NTCP) for cholestatic diseases[40]. - The company’s lead program, AX-0810, targets cholestatic diseases and has received clinical trial authorization for a Phase 1 study, with the first healthy volunteer dosed in December 2025[63]. - The development of drug candidates is lengthy, uncertain, and expensive, with a high historical failure rate for product candidates due to various factors[69]. - The company has faced setbacks in its previous clinical trials, including the Phase 2/3 trial of sepofarsen, which did not meet its primary endpoint[59]. - The company may need to conduct additional clinical trials to obtain regulatory approval, which could further delay commercialization[75]. - The company is developing an RNA editing platform using proprietary Axiomer RNA editing technology for genetic disorders with unmet needs, but the scientific research is still preliminary and not clinically validated[78]. Regulatory and Compliance Risks - Regulatory approval processes for product candidates are lengthy and unpredictable, requiring extensive preclinical and clinical trials before marketing applications can be submitted[65]. - The company may incur significant additional costs to comply with potential new SEC climate-related disclosure rules, which could impact operational expenses[57]. - The company is subject to extensive regulations regarding the distribution of biopharmaceutical products, which include record-keeping and licensing requirements[102]. - Non-compliance with healthcare laws could result in significant penalties, including civil and criminal liabilities, which may adversely affect the company's operations and financial results[104]. - The company is subject to complex tax laws and regulations that may change, potentially leading to increased tax liabilities and operational costs[161]. - The company is subject to extensive ongoing regulatory requirements post-approval, which may impose additional costs and operational challenges[151]. - The company may face challenges in international markets due to varying reimbursement and healthcare payment systems, which could restrict its ability to commercialize products[148]. Funding and Capital Requirements - As of December 31, 2025, the company had €92,413,000 in cash and cash equivalents, which is expected to fund operations into mid-2027[49]. - Future capital requirements may vary significantly, and the company may need to seek additional funding sooner than planned due to uncertainties in development timelines[49]. - The company has received funding of $6.8 million from Foundation Fighting Blindness to advance ultevursen into the clinic, with repayments settled upon the sale of ultevursen[47]. Collaborations and Partnerships - The company has entered into a licensing and research collaboration agreement with Lilly, focusing on potential new medicines in the peripheral nervous system and metabolic diseases[87]. - The company announced a new research partnership with the Rett Syndrome Research Trust to develop editing oligonucleotides targeting a genetic variant causing Rett syndrome, included in the pipeline as AX-2402[87]. - The company relies on Théa for the development and commercialization of sepofarsen and ultevursen, and any failure by collaborators could significantly reduce future revenue potential[90]. - Collaborations are subject to risks, including collaborators' discretion in resource allocation and potential delays in clinical trials, which could negatively impact financial results[91]. Intellectual Property Risks - The company faces risks related to intellectual property, including potential litigation that could adversely affect its business and financial performance[110]. - The company must comply with various procedural requirements to maintain patent protection, and failure to do so could result in loss of patent rights[111]. - The company may need to litigate to protect its intellectual property rights, which could be costly and time-consuming[112]. - Third-party claims of patent infringement could lead to significant legal challenges and impact the company's ability to commercialize its products[115]. - Protecting intellectual property rights globally is expensive, and competitors may exploit technologies in jurisdictions without patent protection[121]. Operational Risks - The company faces risks related to dependence on third-party collaborators, which could delay or terminate the development and commercialization of product candidates[87]. - The company relies on third-party manufacturers for clinical and commercial supplies, and any disruptions in supply could hinder product development and commercialization[93]. - Delays in preclinical and clinical studies due to third-party performance issues could have materially adverse effects on the company's financial condition and prospects[96]. - The company faces risks related to outsourcing functions to third parties, including potential misappropriation of proprietary information and limited internal resources to manage these relationships[98]. - The company is dependent on attracting and retaining qualified key management and technical personnel, with increased competition for talent in specialized fields[166]. Market and Competitive Risks - The company faces significant competition from larger entities with more resources, which could impact its ability to develop and commercialize products[126]. - Reimbursement from third-party payors is essential for the commercial success of any approved product, and uncertainty exists regarding coverage and reimbursement levels[127]. - Legislative changes, such as the Affordable Care Act, may negatively impact the company's ability to profitably sell its product candidates[135]. - Market acceptance of product candidates will depend on various factors, including safety, effectiveness, and pricing compared to existing treatments[136]. Cybersecurity and Data Protection Risks - The company faces risks from cybersecurity incidents and data breaches, which could lead to regulatory fines and damage to its reputation[180]. - The company relies on technology systems for data processing and regulatory compliance, making it vulnerable to cyberattacks and data breaches[178]. - The company must comply with various international data protection laws, which may impose additional operational and compliance costs[173]. Economic and Macroeconomic Risks - Unstable macroeconomic conditions may adversely affect the company's business operations and financial performance[210]. - Changes in U.S. federal policies and tariffs could negatively impact the company's business and market conditions[211].